Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.59T
24h Vol:
$2.88B
Dominance:
MSFT:5.16%
Stocklytics Platform
BETA
Instrument logo  CAPR

Capricor Therapeutics Inc

CAPR
60 / 100
Penny Stock
$4.13arrow_drop_up4.41%$0.17
Key Stats
Open$3.85
Prev. Close$3.88
EPS-1.16
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap120400239.00
PE Ratio-
LOWHIGH
Day Range3.85
4.12
52 Week Range2.68
8.22
Ratios
P/B Ratio7.73
Revenue$14.04M
Operating M. %-110.97%
Earnings$0.00
Earnings Growth %-0.78%
EBITDA Margin %-212.88%
ROE %-428.87%
EPS-1.16
Fundamentals
RPS$0.55
Gross Profit-
EBITDA-$29.91M
Total Debt$2.41M
P/S Ratio8.5x
Enterprise to EBITDA-3.14
Profit Margin-208.16%
ROA-42.36%
Debt/Equity Ratio-
Payout Ratio-
Industry average yield3.04%
Last Dividend pay dateJun 5, 2019
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CAPRarrow_drop_up0.77%
US Healthcare Sectorarrow_drop_up0.65%
US Marketarrow_drop_up0.51%
CAPR / Market
CAPR exceeded the US Market which returned 0.51% over the last twenty four hours.
CAPR / Healthcare Sector
CAPR exceeded the US Healthcare sector which returned 0.65% over the last twenty four hours.

Capricor Therapeutics Inc (CAPR) Statistics

Capricor Therapeutics Inc (CAPR) is a biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases. The company's mission is to improve the lives of patients with unmet medical needs through innovative and effective treatments. Capricor is dedicated to delivering value to its shareholders through its strong commitment to research and development, as well as its focus on commercialization and strategic partnerships.

When evaluating the valuation metrics of Capricor Therapeutics Inc (CAPR), it is important to consider various factors. The company's market capitalization, which is calculated by multiplying the current stock price by the total number of outstanding shares, provides an indication of the overall value of the company. Additionally, metrics such as price-to-earnings ratio, price-to-sales ratio, and price-to-book ratio can provide insights into the relative value of the stock compared to its peers and the broader market.

add Capricor Therapeutics Inc to watchlist

Keep an eye on Capricor Therapeutics Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
How has Capricor Therapeutics Inc (CAPR) stock's performance compared to its sector and the market over the past year?

Over the past year, Capricor Therapeutics Inc (CAPR) has experienced a price change of -13.3%. Compared to the Healthcare sector, which saw a change of 35.06%, Capricor Therapeutics Inc has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 39.12%, it has fallen short of the market average. This comparison highlights Capricor Therapeutics Inc's performance relative to both its sector and the overall market over the last year.

question_mark
What is the PE ratio of Capricor Therapeutics Inc (CAPR) stock?

The PE ratio for Capricor Therapeutics Inc (CAPR) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

question_mark
What is the EPS of Capricor Therapeutics Inc (CAPR) stock?

The Earnings Per Share (EPS) for Capricor Therapeutics Inc (CAPR), calculated on a diluted basis, is -$1.16. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

question_mark
What is the operating margin of Capricor Therapeutics Inc (CAPR) stock?

The operating margin for Capricor Therapeutics Inc (CAPR) is -110.97%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

question_mark
What is the EBITDA of Capricor Therapeutics Inc (CAPR) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Capricor Therapeutics Inc (CAPR) is -$29.91M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

question_mark
How much debt does Capricor Therapeutics Inc (CAPR) have?

Capricor Therapeutics Inc (CAPR) has a total debt of $2.41M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$6.57M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.